Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of the Auditors. Shareholders granted discharge Weiterlesen…
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other 510(k)-cleared bone grafts on the market Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, Weiterlesen…
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics Weiterlesen…